1BT Stock Chart & Stats
€3.76
-€0.18(-4.57%)
At close: 4:00 PM EDT
€3.76
-€0.18(-4.57%)
Day’s Range― - ―
52-Week Range€1.25 - €15.30
Previous CloseN/A
Volume0.00
Average Volume (3M)1.00
Market Cap
€20.37M
Enterprise Value€28.67
Total Cash (Recent Filing)€5.87M
Total Debt (Recent Filing)€641.00K
Price to Earnings (P/E)<0.1
Beta0.56
Next Earnings
Apr 23, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)405.30
Shares Outstanding17,485,462
10 Day Avg. Volume0
30 Day Avg. Volume1
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.02
Price to Sales (P/S)0.00
P/FCF Ratio-3.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€69.05Price Target Upside1736.39% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.05
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
FDA RMAT Designation Strengthens Allocetra's Development PathwayRMAT status provides enhanced FDA interaction and a potentially faster regulatory pathway. Combined with reported durable Phase I/IIa improvements and an ongoing Phase IIb trial, it strengthens the program's development prospects.
Large Private Placement Could Fund Clinical Development And Reduce Near-term Financing PressureIf completed, the financing could provide substantial resources for Allocetra's clinical programs, debt repayment and corporate operations. Access to capital is strategically important for a company without product revenue.
Low Leverage Limits Balance-sheet RiskVery low leverage reduces mandatory interest and principal burdens relative to more highly indebted biotechs. This gives Enlivex greater balance-sheet flexibility while it funds trials and seeks regulatory approval.
Bears Say
No Meaningful Product Revenue And Persistent Operating LossesEnlivex has no established commercial revenue base to support operations, and its losses are not being offset by improving operating performance. Sustainable growth therefore remains dependent on successful clinical execution and future approval.
Ongoing Cash Burn Creates Continuing Dependence On External FundingPersistent cash consumption limits financial self-sufficiency and may require additional equity, debt or partnerships before commercialization. Repeated financing needs can increase dilution and constrain the pace of long-term development.
Digital-asset Treasury Exposure Adds Structural Balance-sheet And Strategy RiskA large, volatile token position materially changes the company's risk profile beyond clinical biotechnology. Treasury value, liquidity and capital allocation become tied to digital-asset markets, potentially distracting from or amplifying risks in the drug pipeline.
Enlivex News
1BT FAQ
What was Enlivex Therapeutics Ltd’s price range in the past 12 months?
Enlivex Therapeutics Ltd lowest stock price was €1.25 and its highest was €15.30 in the past 12 months.
What is Enlivex Therapeutics Ltd’s market cap?
Enlivex Therapeutics Ltd’s market cap is €20.37M.
When is Enlivex Therapeutics Ltd’s upcoming earnings report date?
Enlivex Therapeutics Ltd’s upcoming earnings report date is Apr 23, 2027 which is in 236 days.
How were Enlivex Therapeutics Ltd’s earnings last quarter?
Enlivex Therapeutics Ltd released its earnings results on May 22, 2026. The company reported -€0.017 earnings per share for the quarter, the consensus estimate of -€0.017 by €0.
Is Enlivex Therapeutics Ltd overvalued?
According to Wall Street analysts Enlivex Therapeutics Ltd’s price is currently Undervalued.
Does Enlivex Therapeutics Ltd pay dividends?
Enlivex Therapeutics Ltd does not currently pay dividends.
What is Enlivex Therapeutics Ltd’s EPS estimate?
Enlivex Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Enlivex Therapeutics Ltd have?
Enlivex Therapeutics Ltd has 17,485,462 shares outstanding.
What happened to Enlivex Therapeutics Ltd’s price movement after its last earnings report?
Enlivex Therapeutics Ltd reported an EPS of -€0.017 in its last earnings report, expectations of -€0.017. Following the earnings report the stock price went up 2.521%.
Which hedge fund is a major shareholder of Enlivex Therapeutics Ltd?
Currently, no hedge funds are holding shares in DE:1BT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Enlivex Therapeutics Ltd
Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy.
1BT Stock 12 Month Forecast
Average Price Target
€69.05
▲(1736.39% Upside)